cardiovascular outcomes Archives -

A single tablet that contains four generically-available drugs – or ‘polypill’ – could offer an effective, low-cost way

Low-cost polypill could dramatically cut heart attacks, strokes

https://pharmaphorum.com/news/low-cost-polypill-could-dramatically-cut-heart-attacks-strokes/

AstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2

AZ’s Forxiga gets heart claim data on its EU label

https://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/

Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failure

https://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/

Merck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin

Pfizer and Merck’s diabetes contender looks to challenge Jardiance

https://pharmaphorum.com/news/pfizer-merck-file-diabetes-contender-us-eu/

cardiovascular outcomes